The Department of Defense's Defense Health Agency awarded Duke University a $724,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct research titled "TARGETING DORMANCY-ASSOCIATED IMMUNE TOLERANCE TO ELIMINATE RESIDUAL BREAST CANCER." The 3-year grant, which began on March 1, 2025, supports Duke's efforts to explore innovative immunological interventions for addressing dormant breast cancer cells and eliminating residual disease. As a leading research institution, Duke University's Office of Research Administration Division has extensive experience managing federal grants and contracts across various biomedical and scientific domains, including cancer research, brain studies, and advanced technology development. This award demonstrates Duke's capabilities in conducting critical military medical research to improve health outcomes for service members and the broader public.
Generated 3/4/25, 8:18 AM